Latest Vestal Point Capital, LP Stock Portfolio
$1.34Billion– No. of Holdings #60
Vestal Point Capital, LP Performance:
2024 Q2: -9.25%YTD: -9%
Performance for 2024 Q2 is -9.25%, and YTD is -9%.
About Vestal Point Capital, LP and 13F Hedge Fund Stock Holdings
Vestal Point Capital, LP is a hedge fund based in NEW YORK, NY. On 10-Aug-2023, the fund reported that it had an AUM (Regulated Assets under Management) of $1.3 Billions. In it's latest 13F Holdings report, Vestal Point Capital, LP reported an equity portfolio of $1.3 Billions as of 30 Jun, 2024.
The top stock holdings of Vestal Point Capital, LP are JAZZ, CYTK, . The fund has invested 11.9% of it's portfolio in JAZZ PHARMACEUTICALS PLC and 8.4% of portfolio in CYTOKINETICS INC.
The fund managers got completely rid off NEUROCRINE BIOSCIENCES INC (NBIX), ALNYLAM PHARMACEUTICALS INC (ALNY) and ASTRAZENECA PLC stocks. They significantly reduced their stock positions in INARI MEDICAL INC (NARI), GLOBUS MEDICAL INC (GMED) and LIQUIDIA CORP (LQDA). Vestal Point Capital, LP opened new stock positions in JANUX THERAPEUTICS INC (JANX), SAVARA INC (SVRA) and ITEOS THERAPEUTICS INC (ITOS). The fund showed a lot of confidence in some stocks as they added substantially to ULTRAGENYX PHARMACEUTICAL INC (RARE), EXACT SCIENCES CORP (EXAS) and ARCELLX INC (ACLX).
The top stock holdings of Vestal Point Capital, LP are JAZZ, CYTK, . The fund has invested 11.9% of it's portfolio in JAZZ PHARMACEUTICALS PLC and 8.4% of portfolio in CYTOKINETICS INC.
The fund managers got completely rid off NEUROCRINE BIOSCIENCES INC (NBIX), ALNYLAM PHARMACEUTICALS INC (ALNY) and ASTRAZENECA PLC stocks. They significantly reduced their stock positions in INARI MEDICAL INC (NARI), GLOBUS MEDICAL INC (GMED) and LIQUIDIA CORP (LQDA). Vestal Point Capital, LP opened new stock positions in JANUX THERAPEUTICS INC (JANX), SAVARA INC (SVRA) and ITEOS THERAPEUTICS INC (ITOS). The fund showed a lot of confidence in some stocks as they added substantially to ULTRAGENYX PHARMACEUTICAL INC (RARE), EXACT SCIENCES CORP (EXAS) and ARCELLX INC (ACLX).
Vestal Point Capital, LP Equity Portfolio Value
Last Reported on: 14 Aug, 2024
Vestal Point Capital, LP Annual Return Estimates Vs S&P 500
Our best estimate is that Vestal Point Capital, LP made a return of -9.25% in the last quarter. In trailing 12 months, it's portfolio return was NA%.
New Buys
| Ticker | $ Bought |
|---|---|
| janux therapeutics inc | 30,370,200 |
| savara inc | 26,154,700 |
| iteos therapeutics inc | 25,970,000 |
| axsome therapeutics inc | 24,150,000 |
| structure therapeutics inc | 21,991,200 |
| bristol-myers squibb co | 20,765,000 |
| day one biopharmaceuticals inc | 17,225,000 |
| immunome inc | 12,100,000 |
New stocks bought by Vestal Point Capital, LP
Additions
| Ticker | % Inc. |
|---|---|
| ultragenyx pharmaceutical inc | 1,536 |
| exact sciences corp | 825 |
| arcellx inc | 575 |
| lexeo therapeutics inc | 380 |
| kalvista pharmaceuticals inc | 251 |
| pacira biosciences inc | 250 |
| astria therapeutics inc | 195 |
| solid biosciences inc | 157 |
Additions to existing portfolio by Vestal Point Capital, LP
Reductions
| Ticker | % Reduced |
|---|---|
| inari medical inc | -56.25 |
| globus medical inc | -10.00 |
| liquidia corp | -8.5 |
| soleno therapeutics inc | -4.00 |
| cytokinetics inc | -3.49 |
Vestal Point Capital, LP reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| geron corp | -7,260,000 |
| tg therapeutics inc | -15,970,500 |
| lyra therapeutics inc | -4,976,000 |
| neurocrine biosciences inc | -97,923,200 |
| novavax inc | -2,390,000 |
| astrazeneca plc | -27,100,000 |
| alnylam pharmaceuticals inc | -52,307,500 |
| alpine immune sciences inc | -13,874,000 |
Vestal Point Capital, LP got rid off the above stocks
Sector Distribution
Vestal Point Capital, LP has about 84.2% of it's holdings in Healthcare sector.
| Sector | % |
|---|---|
| Healthcare | 84.2 |
| Others | 15.8 |
Market Cap. Distribution
Vestal Point Capital, LP has about 11.9% of it's portfolio invested in the large-cap and mega-cap stocks.
| Category | % |
|---|---|
| MID-CAP | 43.5 |
| SMALL-CAP | 25.6 |
| UNALLOCATED | 15.8 |
| LARGE-CAP | 8.2 |
| MEGA-CAP | 3.7 |
| MICRO-CAP | 3.1 |
Stocks belong to which Index?
About 40.1% of the stocks held by Vestal Point Capital, LP either belong to S&P 500 or RUSSELL 2000 index.
| Index | % |
|---|---|
| Others | 59.8 |
| RUSSELL 2000 | 38.6 |
| S&P 500 | 1.5 |
Vestal Point Capital, LP Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Vestal Point Capital, LP
Vestal Point Capital, LP has 60 stocks in it's portfolio. About 54.9% of the portfolio is in top 10 stocks. CYTK proved to be the most loss making stock for the portfolio. INSM was the most profitable stock for Vestal Point Capital, LP last quarter.
Last Reported on: 14 Aug, 2024| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| ACHL | achilles therapeutics plc | 0.09 | 1,500,000 | 1,222,500 | unchanged | 0.00 | ||
| ACLX | arcellx inc | 2.78 | 675,000 | 37,253,200 | added | 575 | ||
| AGIO | agios pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALLO | allogene therapeutics inc | 0.38 | 2,200,000 | 5,126,000 | added | 62.96 | ||
| ALNY | alnylam pharmaceuticals inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALPN | alpine immune sciences inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ALXO | alx oncology holdings inc | 1.62 | 3,600,000 | 21,708,000 | added | 37.93 | ||
| APLS | apellis pharmaceuticals inc | 0.96 | 335,000 | 12,850,600 | added | 48.89 | ||
| APLT | applied therapeutics inc | 1.89 | 5,430,000 | 25,358,100 | added | 6.26 | ||
| ATRA | atara biotherapeutics inc | 0.07 | 112,000 | 952,000 | new | |||
| ATRA | atara biotherapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| ATXS | astria therapeutics inc | 2.20 | 3,250,000 | 29,575,000 | added | 195 | ||
| AXSM | axsome therapeutics inc | 1.80 | 300,000 | 24,150,000 | new | |||
| BDTX | black diamond therapeutics inc | 0.73 | 2,100,000 | 9,786,000 | new | |||
| BGNE | beigene ltd | 3.72 | 350,000 | 49,934,500 | added | 7.69 | ||
| BIO | bio-rad laboratories inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BMRN | biomarin pharmaceutical inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| BMY | bristol-myers squibb co | 1.55 | 500,000 | 20,765,000 | new | |||
| CMRX | chimerix inc | 0.09 | 1,400,000 | 1,226,400 | unchanged | 0.00 | ||
| CYTK | cytokinetics inc | 8.38 | 2,075,000 | 112,424,000 | reduced | -3.49 | ||